Patents Assigned to AGEX THERAPEUTICS, INC.
-
Patent number: 11977073Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.Type: GrantFiled: October 22, 2019Date of Patent: May 7, 2024Assignee: AgeX Therapeutics, Inc.Inventor: Basil M. Hantash
-
Publication number: 20220316013Abstract: The present invention relates to compositions and methods for the assay, diagnosis, prognosis or monitoring of the embryonic, fetal, and adult epigenetic states of a human genome. The disclosed methods are useful in monitoring the progress of in vitro and in vivo cellular reprogramming and the diagnosis, prognosis or monitoring of cancer in an individual. Specifically, the invention provides methods for the detection and interpretation of observed differential DNA methylation patterns and associated epigenetic modifications to core histones in determining the developmental status of human cells for the detection and characterization of cancer cells and determining optimum therapeutic modalities.Type: ApplicationFiled: August 25, 2020Publication date: October 6, 2022Applicant: AgeX Therapeutics, Inc.Inventors: Michael D. West, Karen B. Chapman
-
Publication number: 20210338822Abstract: The invention provides improved methods, compositions, uses and kits relating to exosomes isolated from cells and therapeutic compositions and methods of using those exosomes. In one embodiment, the exosomes are loaded with one or more molecules to provide a desired therapeutic effect.Type: ApplicationFiled: January 22, 2021Publication date: November 4, 2021Applicant: AgeX Therapeutics, Inc.Inventors: Dana LaRocca, Jieun Lee, Hal Sternberg
-
Publication number: 20210180013Abstract: Aspects of the present invention include compositions and methods for discovering novel compositions and applying said compositions in treating medical conditions including aging, degenerative disease, wound treatment, and cancer through the modulation of molecular pathways regulating regeneration and senolysis by means of altering the embryonic-fetal and prenatal/postnatal transitional states of mammalian cells.Type: ApplicationFiled: April 23, 2019Publication date: June 17, 2021Applicant: AgeX Therapeutics, Inc.Inventors: Michael D. West, Hal Stemberg
-
Patent number: 10961531Abstract: Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.Type: GrantFiled: June 3, 2014Date of Patent: March 30, 2021Assignee: AgeX Therapeutics, Inc.Inventors: Michael D. West, Karen Chapman, Hal Sternberg
-
Publication number: 20200306296Abstract: Exosomes are generated from host embryonal carcinoma or embryonic progenitor cell lines and used for induced tissue regeneration. These inventive compositions and methods provide for induced tissue regeneration in aged or diseased mammalian tissues in vivo without the use of transgenically-expressed genes. Cells are reprogrammed to a prenatal, indeed a pre-fetal state, as indicated by for example in the case of many stromal cell types, by a decrease in the markers ADIRF and COX7A1.Type: ApplicationFiled: March 27, 2020Publication date: October 1, 2020Applicant: AgeX Therapeutics, Inc.Inventors: Michael West, Dana Larocca, Jieun Lee
-
Publication number: 20200309776Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.Type: ApplicationFiled: March 27, 2020Publication date: October 1, 2020Applicants: AgeX Therapeutics, Inc., AgeX Therapeutics, Inc.Inventor: Basil M. HANTASH
-
Publication number: 20200225213Abstract: A method of screening a composition for cardiotoxicity comprising contacting the composition with cardiomyocytes that have increased fatty acid oxidation and/or diminished glucose oxidation. The cardiomyocytes are preferably prepared by overexpression of COX7A1. The cardiomyocytes are preferably provided in a micropatterned co-culture to provide a mature functional hPSC-CM cardiotoxicity model.Type: ApplicationFiled: January 7, 2020Publication date: July 16, 2020Applicant: AgeX Therapeutics, Inc.Inventors: Michael D. West, Jeffrey Janus
-
Patent number: 10502738Abstract: Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.Type: GrantFiled: June 16, 2017Date of Patent: December 10, 2019Assignee: AGEX THERAPEUTICS, INC.Inventor: Basil M. Hantash